Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.
Back
Dr Jain on the Role of JAK Inhibition in Polycythemia Vera and Myelofibrosis
Akriti G. Jain, MD, discusses the role of JAK inhibition in polycythemia vera and myelofibrosis.
Dr Jain on the Role of JAK Inhibition in Polycythemia Vera and Myelofibrosis
Episodes
All
All
Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.
Akriti G. Jain, MD, discusses factors that affect treatment sequencing with JAK inhibitors for the treatment of patients with myelofibrosis.
Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5